In light of such mechanisms, we may need to consider the use of inhibitors of mutated (i.e., hyper-activated) Ras in patients who do not have any apparent constitutive activation of the oncogene due to its mutation and also express high levels of TNFα, as is the case for many breast cancer patients. This evidence concerns the gene TNF and breast cancer.